Related Experiment Videos
Divergence and complexities in DAG signaling: looking beyond PKC.
ChengFeng Yang1, Marcelo G Kazanietz
1Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6160, USA.
Trends in Pharmacological Sciences
|November 11, 2003
Summary
Understanding protein kinase C (PKC) signaling is crucial for cancer treatment. New research highlights the complexity of PKC pathways and the need for tools to distinguish PKC from non-PKC receptors for targeted therapies.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Protein kinase C (PKC) is a key target for cancer and disease treatment.
- Understanding PKC isozyme roles in cell proliferation, survival, and transformation requires examining PKC-mediated signal transduction.
- Selectivity issues with PKC activators/inhibitors and pathway cross-talk complicate PKC response analysis.
Purpose of the Study:
- To clarify the role of PKC isozymes in cellular processes.
- To address the complexity of PKC-mediated signaling and identify non-PKC pathways.
- To guide the development of selective therapeutic strategies targeting PKC.
Main Methods:
- Isozyme-specific intervention to examine PKC-mediated signal transduction pathways.
- Analysis of phorbol ester-regulated pathways.
- Identification of diacylglycerol (DAG) signal transducers beyond PKC.
Main Results:
- PKC isozyme function is complicated by cross-talk and non-selective agents.
- Diacylglycerol (DAG) signals can be mediated by non-PKC receptors like chimaerins, RasGRPs, MUNC13s, PKD, and DAG kinases.
- Some effects attributed to PKC may involve PKC-independent pathways.
Conclusions:
- A comprehensive analysis of isozyme-specific pathways is essential.
- Development of pharmacological and molecular tools is needed to differentiate PKC and non-PKC phorbol ester receptors.
- This research is key for designing novel therapeutic strategies targeting PKC isozymes.